# 1. Financial Performance ## A. Key Figures * **Revenue (Q4 FY26):** **₹721.1 Cr** Consolidated (+6% YoY / +20% QoQ) * **EBITDA (Q4 FY26):** **₹96.6 Cr** Consolidated (Flat YoY / +72% QoQ) · **13.4%** Margin * **PAT (Q4 FY26):** **₹55.3 Cr** Consolidated (-12% YoY / +36% QoQ) · **7.7%** Margin * **Debt:** **₹328 Cr** Long-term · **₹248 Cr** Short-term * **Planned Capex:** **₹300 Cr – ₹400 Cr** Over next 2-3 years ## B. Revenue & Margin Profile * **Sequential Recovery:** Performance showed a sharp rebound in the final quarter, driven by stabilizing prices, a stronger export profile, and the ramp-up of new facilities. * **Margin Dynamics:** While quarterly profitability saw a significant sequential jump, overall margins face pressure from **₹18 Cr – ₹20 Cr** in EBITDA losses related to the ramp-up of methylamine and salicylic acid projects. * **Mix Optimization:** Management is targeting a return to historical margin levels by increasing regulated sales, expanding the formulations business, and commissioning a new **oncology facility**. * **Pricing Sensitivity:** Gross margin percentages may fluctuate if raw material costs spike, though the company aims to maintain stable **absolute gross profit per kg**. ## C. Debt & Leverage * **Balance Sheet Strength:** The company has achieved its **historically lowest debt-to-equity ratio**, reflecting disciplined capital management despite ongoing expansion. ## D. Capital Expenditure & R&D * **Strategic Expansion:** Capex is focused on quasi-greenfield and brownfield projects across **3-4 locations** to deepen existing capabilities rather than diversifying into unrelated lines. * **Execution Timeline:** Major capitalization of formulation projects is expected after the next **24 months**; total spend may scale up if cash flows from Sayakha and salicylic projects exceed expectations. * **R&D De-risking:** The R&D strategy prioritizes late-stage development, ensuring dossiers or approvals are imminent before committing to major contracts. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Sayakha Plant Utilization:** **~29%** Q3 FY26 · **>40%** Q4 FY26 · **~60%** Q1 FY27 (First Half) * **Production Volume:** **~1,000 tonnes/month** Sayakha methylamines (March 2026) * **Capital Work-in-Progress (CWIP):** **₹214 Cr** (Cogen boiler, brownfield projects, R&D) ## B. Plant Utilization & Scale-up * **Accelerated Ramp-up:** Methylamine operations at Sayakha show consistent sequential utilization growth, reaching over half-capacity in early Q1 despite minor raw material shortages. * **Operational Stability:** Management notes the Sayakha scale-up is progressing smoothly, avoiding the historical technical challenges encountered at the Tarapur facility. * **Future Trajectory:** Further utilization gains are expected throughout FY 2027, closely indexed to the company's internal demand for metformin production. ## C. Backward Integration & Cost Leadership * **Metformin Self-Sufficiency:** Successful indigenous procurement and integration of a key intermediate positions the company as the sole player with such a facility, enhancing cost-competitiveness. * **Margin Drivers:** Strategic focus on reducing external input dependence for the metformin portfolio is expected to unlock significant operating leverage and margin expansion. ## D. Expansion Projects & Strategy * **Capital Efficiency:** The "quasi-greenfield" strategy leverages existing utility and administrative infrastructure to deliver higher asset turns than traditional greenfield investments. * **Project Delays:** The derivatives plant launch is deferred to **late May or mid-June 2026** due to localized labor shortages and utility supply constraints. * **Formulation Growth:** Brownfield capacity enhancements are underway to support forecasted demand for existing products and a new pipeline of **oncology dossiers**. ## E. Operational Efficiency * **Technical Status:** Internal hurdles are currently limited to minor drying issues for a specific methylamine derivative, which are not expected to impact the broader utilization uptrend. --- # 3. Product & Segment Performance ## A. Key Figures * **Formulation Revenue:** **₹91.3 Cr** Q4 FY26 (+41%) · **₹330.5 Cr** FY26 (+16%) * **Formulation Export Mix:** **69%** Q4 FY26 · **65%** FY26 * **Formulation EBITDA Margin:** **16% to 17%** (Last two quarters) * **API Therapy Mix (Sales %):** **37.8%** Antibiotic · **19.6%** Anti-protozoal · **15.0%** Antidiabetic · **11.9%** Anti-inflammatory · **10.0%** Anti-fungal ## B. Formulation Growth & Strategy * **Export-Led Momentum:** Robust double-digit revenue growth driven by direct exports of the non-oncology portfolio and increasing product approvals in regulated markets. * **Long-term Scaling:** Management has set a strategic target to scale segment revenue to **₹1,000 Cr** within the next **3 to 5 years**. * **Capacity Expansion:** Planned CAPEX is focused on **doubling capacity** of the EDQM-certified Oral Solid Dosage (OSD) block to support volume growth. ## C. Salicylic Acid Derivatives * **Operational Pivot:** Production is temporarily halted to mitigate variable losses; the company is transitioning from the base product to higher-value derivatives to capture better pricing and margins. * **Efficiency Initiatives:** Recovery is contingent on new equipment installation for **phenol recovery** and the implementation of a liquid extractor to improve cost competitiveness against Chinese imports. * **Regulatory & Integration:** Strategy includes pursuing **antidumping duties** and commissioning a forward integration plant, currently moving into piloting and scale-up phases. ## D. Oncology Pipeline * **Pre-Revenue Status:** The oncology plant remains in the developmental stage with dossiers currently being filed for the --- # 4. Geography & Market Mix ## A. Key Figures * **Q4 Revenue Mix:** **₹631.7 Cr** Standalone Revenue · **88%** Consolidated Contribution · **63%** Domestic · **37%** Export * **Q4 Growth:** **+7%** Domestic YoY · **-7%** Export YoY * **FY26 Market Mix:** **38%** Export Contribution (vs. 35% FY25) · **73%** Regulated Market Contribution (vs. 66% FY25) ## B. Market Dynamics & Strategy * **Structural Shift Toward Regulated Markets:** Significant expansion in regulated market share was primarily fueled by **Latin American** gains, marking a transition in the global revenue profile. * **Metformin Leadership:** Maintained dominant market share in **Rest of the World (ROW)** and semi-regulated regions by leveraging cost-competitive production advantages. * **Domestic Demand Sensitivity:** While domestic antibiotic demand remains stable, management noted that high API pricing—similar to the **2023 geopolitical shock**—remains a primary risk to volume growth. ## C. Global Expansion & Approvals * **Regulated Market Pipeline:** Revenue flow from high-value --- # 5. Supply Chain & Operations ## A. Raw Material Sourcing & Risk * **Strategic Dependency:** Key intermediate DCDA remains reliant on imports from **China and Europe**; production is characterized by low margins and high-risk, explosive chemistry. * **Supply Continuity:** Global availability remains largely stable despite geopolitical volatility, with the only notable disruption being a temporary **ammonia sourcing issue** in March. ## B. Input Cost Mitigation * **Macro Headwinds:** Operations faced significant pressure from elevated crude and gas-based input costs, alongside rising freight, packaging, and energy expenses. * **Operational Resilience:** Management deployed process optimization and alternate sourcing strategies to maintain continuity and offset inconsistent material availability. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Crude Price Thresholds:** **$110–$120/bbl** (Demand risk trigger) · **$130–$140/bbl** (API price hike trigger) * Utilization Target: 45%–50% (Methylamine plant - Missed); achieved ~29% (Dec), ~40% (Mar) ## B. Crude Price Volatility & Market Dynamics * **Stabilizing Price Environment:** API pricing trends have firmed up following a period of volatility, with volumes remaining positive despite historical industry-wide pressures. * **Segment-Specific Demand Risks:** Elevated input costs threaten domestic demand for older molecules, particularly antibiotics, where price regulations limit the ability of formulation players to pass on costs. * **Cost Peak Assessment:** Management believes solvent and chemical costs have reached a ceiling, with further API price increases unlikely unless crude breaches significant resistance levels. ## C. Regulatory & Geopolitical Factors * **Trade Protection Measures:** The company has formally submitted an application for **anti-dumping duties on salicylic acid** to counter international competition. * **Environmental Cost Disadvantage:** Negotiations are underway with the government to address the high cost of **evaporation requirements** for effluent disposal, a significant overhead not shared by Chinese peers. * **Geopolitical Supply Chain Impact:** Conflict in West Asia has disrupted **ammonia-based raw material** supplies, leading to a failure to meet utilization targets for the methylamine facility. * **Macroeconomic Transition:** Despite trade tariffs and geopolitical uncertainties, the firm has successfully transitioned from a heavy investment phase to operational scale-up. --- # 7. Guidance & Outlook ## A. Key Figures * **Volume Growth Target:** **8% to 10%** base target · **10% to 15%** internal target * **EBITDA Margin Guidance:** **13.5% to 14%** FY27 target (revised from **14%–14.5%**) * **Gross Contribution Margin:** **+100 bps** minimum improvement target for FY27 * **Capacity Utilization:** **55%–60%** Methylamine plant (June Qtr) · **>70%** within one year * **Export Run Rate:** **₹90 Cr** sustainable target for FY27 ## B. Volume & Margin Expansion Goals * **Growth Drivers:** Robust volume outlook supported by two greenfield expansions; however, antibiotic volumes are expected to remain flattish in FY27 following a weak prior year. * **Profitability Levers:** Margin expansion contingent on increased capacity utilization, backward integration, and a potential **1% reduction** in manufacturing costs. * **Regulatory & Portfolio Tailwinds:** Anticipated margin uplift from higher regulated sales via US FDA-approved facilities, pending Metformin approval, and the scaling of the oncology vertical. * **Macroeconomic Headwinds:** FY27 EBITDA guidance moderated slightly due to volatility in crude oil prices linked to geopolitical tensions. ## C. Utilization & Operational Projections * **Asset Ramp-up:** Significant profitability contributions from the Sayakha plant expected within the next **3 to 4 months**. * **Technical Milestones:** Variable profit in salicylic acid remains dependent on the successful scale-up of pilot batch results and new equipment commissioning. ## D. Long-term Strategy * **Export Sustainability:** Management confirms the current quarterly export run rate is sustainable heading into the next fiscal year. * **Sector Outlook:** FY2027 is expected to see significant price-led growth in the antibiotic sector, offsetting stagnant volumes.